ArticleBMC public health2025
A qualitative exploration of critical issues limiting local vaccines production in Nigeria: lessons from the COVID-19 pandemic.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Catalysing vaccines research, development and manufacturing in Nigeria: a qualitative exploration of industry stakeholders' knowledge, perceptions and experience.Health research policy and systems · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaccines are essential health interventions that have become a cost-effective tool for maintaining public health. Access to vaccines in Nigeria and other developing countries is, however, affected by various relevant issues, including insufficient supply, inequitable distribution, vaccine hesitancy, and a lack of local manufacturing capacity. This study, therefore, aimed to gain an in-depth understanding of the challenges impeding vaccine production in Nigeria, taking lessons from the COVID-19 pandemic.
methodA qualitative study was undertaken using a purposive sampling strategy to recruit key stakeholders across Nigeria's vaccine value chain. Interviews were carried out using a semi-structured interview guide. Relevant stakeholders with varying levels of experience across the vaccine value chain were interviewed to ensure that robust and comprehensive data were obtained. The data collected were subjected to thematic analysis, following the interpretivist tradition. Throughout the study, trustworthiness was assured by adopting relevant processes such as data triangulation, reflexive and audit trails. Ethical approval was obtained from the National Institute for Pharmaceutical Research and Development Health Research Ethics Committee prior to the commencement of data collection.
resultsThis study revealed eight thematic areas underpinning the gaps associated with local vaccine production in Nigeria. Challenges included limited capacity, inadequate research and development, infrastructure deficits, and a sub-optimal environment for vaccine development. Furthermore, the challenges associated with commercialisation and distribution were identified. Findings also revealed a lack of critical factors required for expediting vaccine manufacturing in Nigeria, including poor commitment to collaboration, an absence of sustainability policies and sub-optimal legislation.
conclusionThe study provides insight into systemic and structural barriers to local vaccine production in Nigeria. It identifies key areas requiring urgent intervention, which include funding, infrastructure, human capacity, and regulatory reform. Addressing these gaps through multi-level strategies is critical for improving vaccine self-sufficiency. Evidence from this study can help develop contextual strategies that will expedite vaccine production and Medicines' Security in Nigeria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.